We characterized the population pharmacokinetics of moxidectin using data from Strongyloides stercoralis-infected adult patients treated with moxidectin 2–12 mg.

While body weight influences moxidectin clearance, we found high clearance in S. stercoralis-infected individuals compared with that reported for healthy subjects.

The pharmacokinetic profile of moxidectin shows substantial random variability, where both fixed- and weight-dependent dose strategies result in equivalent variable exposures across body weight. This supports the use of a fixed-dose strategy in large-scale programs for treating strongyloidiasis.